Skip to main content
SpringerLink
Log in

Adjuvant Treatment with Bone-Targeting Agents (Bisphosphonates and Anti-RANK-Ligand Antibody)

  • Chapter
  • First Online:
Breast Cancer

  • 123k Accesses

Abstract

Clinical studies show that bisphosphonates and anti-RANK-ligand antibody can ameliorate bone loss from adjuvant breast cancer therapies, with clear suggestions of additional anticancer benefit at least in postmenopausal patients. Recent long-term studies have provided additional support for a clinical benefit from bone-targeted therapies in the adjuvant breast cancer setting and suggest that they might be an appropriate standard of care. This chapter evaluates the recent clinical evidence for the effectiveness of adjuvant bisphosphonate therapy in breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bouvard B, Hoppe E, Soulie P et al (2012) High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann Oncol 23:1151–1156

    Article  CAS  PubMed  Google Scholar 

  2. Lester J, Dodwell D, McCloskey E, Coleman R (2005) The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 31:115–142

    Article  PubMed  Google Scholar 

  3. Coleman RE, Body J-J, Gralow JR, Lipton A (2008) Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 34(Suppl 1):S31–S42

    Article  CAS  PubMed  Google Scholar 

  4. Abdel-Razeq H, Awidi A (2011) Bone health in breast cancer survivors. J Cancer Res Ther 7:256–263

    Article  PubMed  Google Scholar 

  5. Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:105157

    Article  Google Scholar 

  6. Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol 8:119–127

    Article  CAS  PubMed  Google Scholar 

  7. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729

    Article  CAS  PubMed  Google Scholar 

  8. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840–849

    Article  CAS  PubMed  Google Scholar 

  9. Soiland H, Hagen KB, Gjerde J, Lende TH, Lien EA (2013) Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. Acta Oncol 52:861–862

    Article  PubMed  Google Scholar 

  10. Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433–443

    Article  CAS  PubMed  Google Scholar 

  11. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352

    Article  Google Scholar 

  12. Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546–2555

    Article  CAS  PubMed  Google Scholar 

  13. Reid DM, Doughty J, Eastell R et al (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 34(Suppl 1):S3–S18

    Article  CAS  PubMed  Google Scholar 

  14. Cheung AM, Tile L, Cardew S et al (2012) Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 13:275–284

    Article  CAS  PubMed  Google Scholar 

  15. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ito K, Blinder VS, Elkin EB (2012) Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol 30:1468–1475

    Article  PubMed  Google Scholar 

  17. Hadji P, Aapro M, Costa L, Gnant M (2012) Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations. Cancer Treat Rev 38:815–824

    Article  CAS  PubMed  Google Scholar 

  18. McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831

    Article  CAS  PubMed  Google Scholar 

  19. Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875–4882

    Article  CAS  PubMed  Google Scholar 

  20. Diel IJ, Jaschke A, Solomayer EF et al (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—a long-term follow-up. Ann Oncol 19:2007–2011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Powles TJ, Paterson A, McCloskey E et al (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res Treat 8(R13):1–7

    Google Scholar 

  22. Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691

    Article  CAS  PubMed  Google Scholar 

  23. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Presented at 34th annual San Antonio breast cancer symposium, San Antonio, TX, December 6–10, 2011. Abstract S1–2

    Google Scholar 

  24. Pfeiler G, Konigsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653–2659

    Article  CAS  PubMed  Google Scholar 

  25. Coleman R, de Boer R, Eidtmann H et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-fast study): final 60-month results. Ann Oncol 24:398–405

    Article  CAS  PubMed  Google Scholar 

  26. Coleman RE, Marshall H, Cameron D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396–1405

    Article  CAS  PubMed  Google Scholar 

  27. Von Minckwitz G, Möbus V, Schneeweiss A et al (2013) German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 31:3531–3539

    Article  Google Scholar 

  28. Paterson AH, Anderson SJ, Lembersky BC et al (2012) Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and bowel project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734–742

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Strobl S, Korkmaz B, Devyatko Y et al (2016) Adjuvant bisphosphonates and breast cancer survival. Annu Rev Med 67:1–10

    Article  CAS  PubMed  Google Scholar 

  30. Hadji P, Coleman R, Gnant M, Green J (2012) The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol 23:2782–2790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ottewell PD, Wang N, Brown HK et al (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 20:2922–2932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104:1059–1067

    Article  CAS  PubMed  Google Scholar 

  33. Gnant M, Clezardin P (2012) Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev 38:407–415

    Article  CAS  PubMed  Google Scholar 

  34. Gnant M, Dubsky P, Hadji P (2012) Bisphosphonates: prevention of bone metastases in breast cancer. Recent results. Cancer Res 192:65–91

    CAS  Google Scholar 

  35. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133:571–573

    Article  Google Scholar 

  36. Coleman RE, Winter MC, Cameron D et al (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102(7):1099–1105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Holen I, Ottewell PD, Coleman RE. Zoledronic acid reduces breast tumour growth when combined with chemotherapy—emerging evidence of anti-tumor effects outside bone [poster; abstract P6–14-03]. Presented at: 33rd Annual San Antonio Breast Cancer Symposium San Antonio, TX, December 8–12, 2010

    Google Scholar 

  38. Gnant M (2012) Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? Curr Oncol Rep 14:35–43

    Article  CAS  PubMed  Google Scholar 

  39. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353–1361

    Article  Google Scholar 

  40. Gnant M, Mlineritsch B, Stoeger H et al (2015) Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and colorectal Cancer Study Group Trial 12. Ann Oncol 26:313–320

    Article  CAS  PubMed  Google Scholar 

  41. Gnant M (2014) Role of bisphosphonates in postmenopausal women with breast cancer. Cancer Treat Rev 40:476–484

    Article  CAS  PubMed  Google Scholar 

  42. Coleman R, Hadji P (2015) Denosumab and fracture risk in women with breast cancer. Lancet 386:409–410

    Article  PubMed  Google Scholar 

  43. Gnant M, Pfeiler G, Dubsky P, et al. The impact of adjuvant denosumab on disease-free survival—results from 3,425 postmenopausal patients of the ABCSG-18 trial. Presented at 38rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8–12, 2015

    Google Scholar 

  44. Gnant M (2012) Adjuvant bisphosphonates: a new standard of care? Curr Opin Oncol 24:635–642

    Article  CAS  PubMed  Google Scholar 

  45. Hadji P, Coleman RE, Wilson C et al (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann Oncol 27:379–390

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery–Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Michael Gnant M.D., F.A.C.S.

Authors
  1. Michael Gnant M.D., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Gnant M.D., F.A.C.S. .

Editor information

Editors and Affiliations

  1. European Institutee of Oncology, Milan, Italy

    Umberto Veronesi

  2. European Institute of Oncology, Milan, Italy

    Aron Goldhirsch

  3. European Institute of Oncology, Milan, Italy

    Paolo Veronesi

  4. San Raffaele University and Research Hospital, Milano, Italy

    Oreste Davide Gentilini

  5. European Institute of Oncology, Milan, Italy

    Maria Cristina Leonardi

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gnant, M. (2017). Adjuvant Treatment with Bone-Targeting Agents (Bisphosphonates and Anti-RANK-Ligand Antibody). In: Veronesi, U., Goldhirsch, A., Veronesi, P., Gentilini, O., Leonardi, M. (eds) Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-48848-6_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-48848-6_48

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-48846-2

  • Online ISBN: 978-3-319-48848-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation